You are here

  • Home
  • Archive
  • Volume 78, Issue 6
  • Revisiting the issue of how to assess pneumococcal vaccine immunogenicity: a post hoc analysis of antipneumococcal antibody responses among adult patients with systemic lupus erythematosus previously immunised with 23-valent pneumococcal polysaccharide v…

Article Text

Article menu
Download PDFPDF
Letter
Revisiting the issue of how to assess pneumococcal vaccine immunogenicity: a post hoc analysis of antipneumococcal antibody responses among adult patients with systemic lupus erythematosus previously immunised with 23-valent pneumococcal polysaccharide vaccine
  1. Rodrigo Poubel Rezende1,
  2. Luís Eduardo Coelho Andrade2,
  3. Evandro Mendes Klumb3
  1. 1 Rheumatology, Departamento de Medicina Clínica, Universidade Federal Fluminense, Rio de Janeiro, Brazil
  2. 2 Fleury Medicine and Health Laboratories, Disciplina de Reumatologia, Escola Paulista de Medicina, Universidade Federal de São Paulo, São Paulo, Brazil
  3. 3 Rheumatology, Disciplina de Reumatologia, Universidade do Estado do Rio de Janeiro, Rio de Janeiro, Brazil
  1. Correspondence to Dr Rodrigo Poubel Rezende, Rheumatology, Departamento de Medicina Clínica, Universidade Federal Fluminense, Rio de Janeiro 24033900, Brazil; ropoubel{at}id.uff.br

https://doi.org/10.1136/annrheumdis-2018-214888

Statistics from Altmetric.com

    Request Permissions

    If you wish to reuse any or all of this article please use the link below which will take you to the Copyright Clearance Center’s RightsLink service. You will be able to get a quick price and instant permission to reuse the content in many different ways.

    A judicious analysis and comparison of studies on the immunogenicity of pneumococcal vaccine in patients with systemic lupus erythematosus (SLE)1–9 is hampered by wide heterogeneity in several factors, including differences in the immunoassays performed, cut-off levels used as serological correlates of protection, number of individual serotypes as well as types of capsular antigens analysed, response criteria, and SLE-related immunosuppressive treatment. In addition, how to interpret vaccine response when preimmunisation antipneumococcal antibody titres (anti-PnAbs) are already high (or protective) is not yet clear, which is of relevance given that non-immunised adults often have high antibody levels for some serotypes as a result of prior pneumococcal infections. Moreover, only a minority of individuals with high prevaccination anti-PnAbs are reportedly capable of mounting a ≥4-fold rise in …

    View Full Text

    Footnotes

    • Handling editor Josef S Smolen

    • Contributors RPR and EMK conceived and designed the study, analysed the data and drafted the manuscript. LECA reviewed the manuscript and contributed to the intellectual content of the article.

    • Funding The authors have not declared a specific grant for this research from any funding agency in the public, commercial or not-for-profit sectors.

    • Competing interests None declared.

    • Patient consent for publication Not required.

    • Ethics approval Hospital Universitário Pedro Ernesto.

    • Provenance and peer review Not commissioned; externally peer reviewed.

    • Data sharing statement No additional data available.